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Abstract
Background: Life expectancy in patients with schizophrenia is reduced by 20 years for males and 15 years for
females compared to the general population. About 60% of the excess mortality is due to physical illnesses, with
cardiovascular disease being the single largest cause of death.
Methods/design: The CHANGE trial is an investigator-initiated, independently funded, randomized, parallel-group,
superiority, multi-centre trial with blinded outcome assessment. 450 patients aged 18 years or above, diagnosed
with schizophrenia spectrum disorders and increased waist circumference, will be recruited and randomized 1:1:1 to
12-months interventions. We will compare the effects of 1) affiliation to the CHANGE team, offering a tailored,
manual-based intervention targeting physical inactivity, unhealthy dietary habits, and smoking, and facilitating
contact to their general practitioner to secure medical treatment of somatic comorbidity; versus 2) affiliation to a
care coordinator who will secure guideline-concordant monitoring and treatment of somatic comorbidity by
facilitating contact to their general practitioner; versus 3) treatment as usual to evaluate the potential add-on effects
of lifestyle coaching plus care coordination or care coordination alone to treatment as usual. The primary outcome
is the 10-year risks of cardiovascular disease assessed at 12 months after randomization.
Discussion: The premature mortality observed in this vulnerable population has not formerly been addressed
specifically by using composite surrogate outcomes for mortality. The CHANGE trial expands the evidence for
interventions aiming to reduce the burden of metabolic disturbances with a view to increase life expectancy.
Here, we present the trial design, describe the methodological concepts in detail, and discuss the rationale and
challenges of the intermediate outcomes.
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Background
Schizophrenia is a life shortening disease, with life
expectancy being reduced by 20 years for males and
15 years for females compared to the general population
[1]. About 60% of the excess mortality is due to physical
illness, with cardiovascular disease being the single
largest cause of death [2]. While the general population
has benefitted from a steady decline in ischemic heart
disease since the 1980s, this is not the case for patients
with schizophrenia [3-5].
Death due to cardiovascular disease is closely related to
metabolic syndrome [6]. It has been estimated that the
prevalence of metabolic syndrome in patients with
schizophrenia may be as high as one in three [7]. The
high mortality due to cardiovascular disease can be
explained by unhealthy lifestyle [8], disparities in quality
of health care [9], metabolic adverse effects of anti-
psychotics [10], and probably genetic vulnerability [11].
Of these, lifestyle and use of primary health care might
be considered modifiable factors and thus accessible to
intervention.
Sedentary lifestyle, smoking, and unhealthy dietary
habits are highly prevalent among patients with schizo-
phrenia. A recent study found that patients with schizo-
phrenia spend more than 12 hours on sedentary
activities on a daily basis [12], and make unhealthy diet-
ary choices, consuming more sugar and saturated fats
than the background population [8]. The combination of
pronounced sedentary behaviour and a diet rich in sugar
and fat, highly contributes to the reported proportion of
obesity of 42% to 60% among patients with schizophre-
nia [13]. A significant association between low aerobic
fitness and metabolic syndrome has been found in pa-
tients with schizophrenia [14]. Furthermore, patients
with schizophrenia have more than five times the odds
of being smoker, and smoking cessation is lower than
compared to the general population [15]. Thus, the high
prevalence of cardiovascular disease is multifactorial,
and likely requires a multifaceted intervention.
Several studies have examined the effect of behavioural
and pharmacological interventions targeting single
cardiovascular risk factors like obesity, smoking, glucose-
intolerance, and dyslipidaemia in patients with schizo-
phrenia [16-24]. Weight loss or prevention of weight gain
has been studied in trials aiming to improve unhealthy
diet, physical inactivity, or a combination. Two recent
systematic reviews of randomized clinical trials of lifestyle
interventions conclude that there is significant reduction
of 0.94 kg/m2 [25] and 0.98 kg/m2 [26] in body mass index
(BMI), the latter review finding a superior effect of
combined nutritional counselling and exercise. This is
supported by our own work [27], where exercise as a
single intervention does not seem to affect BMI or other
cardiovascular risk factors [28]. Further support for the
effect of interventions combining exercise and nutrition
has been found recently, in a randomized clinical trial for
weight loss in patients with schizophrenia resulting in a
net difference in BMI of 1.1 kg/m2 between patients in the
intervention group and controls [29]. There is evidence that
bupropion and varenicline increase the chance for smoking
cessation in patients with schizophrenia [24,30,31], but no
randomized clinical trial has combined smoking cessation
with an exercise and nutritional interventions, to maximize
the possibility to reduce cardiovascular disease.
Disparity in quality of primary health care is another
major issue explaining the high mortality. The European
Psychiatric Association [32] and the National Institute for
Health and Care Excellence (NICE) guidelines both recom-
mend that patients with schizophrenia are annually
screened for obesity and cardiovascular risk factors, and
receive guideline concordant prophylactic treatment of
these factors, but this does not appear to happen [33].
Acknowledging the unmet need for primary health care
among patients with schizophrenia, several approaches
have been proposed to fill the gap; an expanded role for the
psychiatrist, an integrative care model with a general practi-
tioner allocated to supported housings or care coordination
providing contact to primary care. Reviewing the literature
in the electronic databases (PubMed, EMBASE, and
Clinical Trials.gov) for studies related to the terms “shared
care, collaborative care and care coordination” and “SMI
(severe mental illnesses) and/or schizophrenia” resulted in
no published studies that have examined the effect of care
coordination on schizophrenia patients in a randomized
clinical trial. We found one ongoing trial assessing the
effect of care management with quality of life as the
primary outcome and cardiovascular risk factors as the
secondary outcome [34]. No results from that trial have yet
been published [34].
Our systematic search revealed no trials or studies
investigating the add-on effect of lifestyle interventions
compared with care coordination alone in a randomized
clinical trial.
Aim and hypothesis
We will compare in a randomized clinical trial the benefits
and harms of 1) lifestyle coaching defined as affiliation to a
CHANGE team member, offering a tailored, manual-based
intervention targeting physical inactivity, unhealthy dietary
habits, smoking, and facilitate contact to their general
practitioner to secure medical treatment of somatic comor-
bidity; versus 2) affiliation to a care coordinator who will
secure guideline-concordant monitoring and treatment of
somatic comorbidity by facilitating contact to their general
practitioner; versus 3) treatment as usual for obese patients
with schizophrenia. The primary outcome of the CHANGE
trial is the estimated 10-years risk of cardiovascular at
12 months post-randomization. Our alternative hypotheses
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are that there will be a reduction in the estimated 10-years
risk of cardiovascular disease in the two experimental
intervention groups compared with the control group, and
that the lifestyle coaching will be more effective than the
care-coordination.
The duration of all interventions is 12 months. Assess-




The CHANGE trial is an investigator-initiated, independ-
ently funded, randomized, parallel-group, superiority, multi-
centre trial with blinded outcome assessment.
Patients
Patients were recruited from well-defined catchment areas
in two major Danish cities (Aarhus and Copenhagen).
Eligible patients were verbally informed by the usual care-
taker, and referred to CHANGE research staff by phone or
e-mail, if accepting. The patients were contacted by phone,
and a meeting was arranged at the research centre, the
outpatient clinic, or at the patient’s home. Verbal and
written information was provided. If the patient accepted
participation in the trial, an informed consent was signed
and an appointment for collection of baseline data was
made. Baseline data were collected between 1st of December
2012 and 1st of May 2014.
Patient inclusion criteria
1) Adults, ≥18 years, fulfilling the ICD-10 diagnostic criteria
for schizophrenia, persistent delusional disorders, or schi-
zoaffective disorders [35] using the Schedule for Clinical
Assessment in Neuropsychiatry (SCAN) [36]; 2) Waist
circumference ≥88 cm for females and ≥102 cm for males
[37] measured between the crista iliac and lowest rib); and
3) Written informed consent.
Patient exclusion criteria
1) Current self-reported pregnancy
2) Inability to consent.
Randomization and blinding
Patients were randomized with a 1:1:1 ratio to either the
lifestyle coaching versus care coordination versus treat-
ment as usual. Randomization was stratified according to
the two psychiatric centres, sex, and a high/low risk of
cardiovascular disease. High risk was defined according to
cut-off points from a Danish population study using the
Copenhagen risk score, aiming to identify the quintile at
highest risk. Each person was - in the computer program
- simulated as 60 years old, to reach a substantial level of
risk [38], This approach is was recommended by the
European cardiovascular risk factor management guide-
lines to asses risk in young individuals [39].
The randomization was centralized and carried out
by the Copenhagen Trial Unit using a computerized
randomization sequence with alternating block sizes
unknown to the investigators. After inclusion in the trial,
a health care provider contacted the Copenhagen Trial
Unit with a unique patient identifier plus stratification
variables and in return received the patient allocation.
Blinding
Outcome assessors, statisticians, and all investigators in-
volved in the trial are blinded to patient allocation. Patients
and the health professionals providing the interventions are
not blinded to patient allocation. The statistical analysis of
the 12 months post randomization follow up and the draft-




The theoretical framework of the lifestyle coaching was
based on the theory of stages of change [40], motivational
interviewing (MI), and an assertive approach adapted from
the assertive community treatment [41]. MI is a method to
help patients elicit their own wishes to change, and it has
been shown effective in patients with schizophrenia and
comorbid alcohol abuse [42]. The assertive approach
allows the staff to be respectfully active and still persistent
in follow-up; be flexible in time; and conduct short
message services, phone calls, home visits or meetings in
the local area.
Manuals (see Additional file 1: care coordinator manual,
Additional file 2: diet manual and Additional file 3:
physical activity manual (Danish)): The three methods
mentioned above, were incorporated in four manuals with
detailed descriptions of the intervention addressing care-
coordination, smoking cessation, healthy diet, and in-
creased physical activity, based on the official Danish
guidelines [43,44]. An important first step was to clarify
possibilities for changes that seem achievable and realistic
according to the stages of change. The aim of the lifestyle
coach was to support the patient in setting up individual
goals that pay attention to the patient’s values, life condi-
tions, and priorities. The coach offered home visits with
systematic exploration of possibilities for physical activity
in daily life, which were realistic and attractive to the
patient. Dietary changes require concrete examination of
the patient’s dietary habits, food purchases and cooking
practices, and identification of economically realistic, easy
and attractive possibilities for change. During home visits,
the coach took part in the activities (ex. physical activity
or food purchases) if requested by the patient, to support
lifestyle changes. Personal and professional networks and
Speyer et al. BMC Psychiatry  (2015) 15:119 Page 3 of 11
patient network could be part of individual plans. The
smoking cessation program was adapted from the pro-
gram published by The National Cancer Organization
[45,46], and tailored to the patient population in order to
elicit and enhance motivation and maintain smoking
cessation. Support was provided for motivation, including
prevention of relapses, and smoking cessation medication.
First line treatment was nicotine substitution and second
line was bupropion.
The staff had access to anthropometric measures and
blood samples collected at baseline and used these in their
first consultation with patients to plan the further course.
Weight was monitored every third month.
Patients commenced the lifestyle coaching as soon as
possible after collection of baseline data, even if they were
in-patients. The coach:patient ratio was 1:15. To allow
sufficient time to implement changes in habits, each
patient was offered affiliation with the team member for
one year and we offered a follow-up after 24 months, to
investigate whether changes in lifestyle and treatment of
physical disorders were maintained one year after the
intervention ended. The lifestyle coach aimed to have
individual meetings or activities with their patients weekly.
Further support was provided by phone calls, e-mails, and
text messages.
The lifestyle coaches and care coordinators performed
written registration of all contact with patients including
cancellations and classification of the focus area of each
consultation, enabling the researchers to evaluate adherence
and program fidelity.
Training and supervision: Lifestyle coaches were health
professionals (e.g., occupational therapist, physiotherapists,
or dieticians) with clinical training in psychiatry. They
received a 5-days course in motivational interviewing, a
5-days course in smoking cessation, a 1-day course in
examination and treatment of lifestyle disorders and a
2-days course on healthy dieting, based on the official
Danish guidelines. During the intervention, supervision of
the team took place weekly. In addition to the interven-
tion described above, the patients were offered care coord-
ination (see below) and treatment as usual.
Care coordinator function
The care coordinator function was incorporated in the
lifestyle intervention as well as the add on treatment in
the second intervention group (see Figure 1). The care
coordinator facilitated contact to primary care in order to
ensure treatment of physical health problems. The care-
coordinator was nurse with a nurse:patient ratio of 1:25.
Affiliation to the care-coordinator was offered for one
year. The intervention was manual-based, and the aim
was to ensure that the patients in this group were
monitored and received guideline-concordant medical
treatment. Their contact with patients comprised personal
meetings, phone calls and text messages, and the fre-
quency of contact was adjusted according to the individual
need. The first meeting with the patient consisted of a
general health talk about the physical well-being and test
results from physical examination performed at baseline.
Special awareness was paid to symptoms of obstructive
pulmonary disease, diabetes and cardiovascular disease.
The care coordinator used the decision tree (Figure 2) to
plan the further course. In addition to the care coordin-
ator intervention described above, the patients continued
treatment as usual.
Treatment as usual
In Denmark all persons have a personal general practi-
tioner and can consult her/him for free when needed.
Patients in secondary mental health services stay affiliated
with their general practitioner, who is responsible for
treating abnormal results from the mandatory yearly
screening of metabolic risk factors. No formalized extra
effort was made regarding lifestyle counselling or treat-
ment of physical disorders. Results from the baseline
assessment were available if requested by the patient or
usual caretakers, and if any of the results was a matter of
urgent consideration, the CHANGE research staff con-
tacted the usual caretaker.
Outcomes
Research staff blinded to patient allocation assesses
outcomes. All patients will be assessed at the following
time points: baseline (T0), 12 months post-randomization
(T1-at completion of intervention), and 24 months post-
randomization (T2).
Figure 1 10 years risk of CVD estimated with Copenhagen Risk Score,
Vo2max =max. oxygen uptake, BP = blood pressure, RHR = resting heart
rate, HbA1c = glycosylated haemoglobin, MVPA =moderate/vigorous
activity, inactivity = sedentary activity, FEV1 = forced expiratory volume.
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Study objectives
The CHANGE trial aims to answer the questions set out
below under primary objectives, secondary objectives and
exploratory objectives.
Primary objectives
1. Is lifestyle coaching plus care coordination more
effective than treatment as usual in reducing risk of
cardiovascular disease 12 months from randomisation?
2. Is lifestyle coaching plus care coordination more
effective than care coordination alone in reducing
risk of cardiovascular disease 12 months from
randomisation?
3. Is care coordination alone more effective than
treatment as usual in reducing risk of cardiovascular
disease 12 months from randomisation?
Primary outcome
The primary outcome is the risk of cardiovascular disease
at 12 months, assessed by the Copenhagen risk score. The
Copenhagen risk score is based on data from two large
epidemiological studies in the Copenhagen area [47].
A risk assessment computer program (PRECARD®)
combines the Copenhagen risk score with data from
randomized clinical trials [47]. This composite measure
includes: sex, family history of CVD (defined as parents
suffering fatal or non-fatal cardiovascular event before the
age of 55 years (father) or 60 years (mother); prior heart
disease (defined as myocardial infarction (MI) or verified
atherosclerosis of coronary arteries); +/- smoking; +/- dia-
betes mellitus (HbA1c-based or receiving anti glycaemic
drugs); total cholesterol, high density lipoprotein choles-
terol (HDL); systolic blood pressure; and body mass index
(weight/height2). Absolute risk is defined as the probability
Figure 2 The decision tree incorporated in the care coordinator function.
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of a clinical event (IHD, MI, stroke, death) happening to a
person within 10 years. Age is simulated to be 60 years, to
reach a substantial level of risk [38], aiming to estimate life
time risk.
Secondary outcomes
Cardiorespiratory fitness was originally defined as an
exploratory outcome, due to insecurity of the acceptability
and feasibility of the test procedure among the recruited
patients. After completed data collection at baseline, we
found an acceptable level of satisfying tests, and redefined
fitness to a key secondary outcome. The patient’s maximal
oxygen uptake (V · O2max) ml oxygen/kg/min was measured
using a bicycle cardiopulmonary exercise test. The test was
based on L. B. Andersens cycle exercise protocol where the
initial 5 min of the cycle test (Monark) the workload is
75 W for women, and 100 W for men (L. B. [48]). Then
the workload is increased by 25 W/2 min till exhaustion.
All patients were continuously verbally encouraged. The
maximum pulse at VO2max was recorded. Forced expiratory
volume (FEV1) measured with Easyone® spirometer.
Physical Activity Scale was used to determine time spent
on moderate and vigorous and sedentary activity a day
[49]. Waist circumference measured between the crista
iliac and lowest rib, blood pressure measured on the right
upper arm after 10 minutes of rest in a sitting position -
the average of the two last consecutive measurements will
be reported, resting heart rate after 10 minutes of rest,
HDL, non-HDL-cholesterol and HbA1c.
Exploratory outcomes
Anthropometric measures: weight in kg and body mass
index, skinfolds measured at four sites (biceps, triceps,
subscapular, suprailiac), and body fat percentage calculated
from skinfold measures [50].
Psychometric measures: positive and negative symptoms
(SAPS and SANS) [51], cognition (BACS) [52], quality
of life (MANSA and EQ-5D) [53], global assessment
of functioning (GAF) [54], perceived health [55], and
perceived stress [56].
Biomedical status measures: triglycerides, high sensitive
CRP (hsCRP), low-density lipoprotein cholesterol (LDL).
Lifestyle measures: food frequency questionnaire [57],
24 hour recall, self-reported point abstinence from smoking
(nicotine dependence questionnaire [58]).
Baseline measures
At baseline, the following was assessed: socio-demographic
data; age, sex, self-reported ethnicity, marital status, eco-
nomic status, work situation, and educational level. Health
care: medical history of diabetes, cardiovascular disease,
cerebrovascular disease, and other past medical history.
Current medication.
Data regarding vital status, causes of death, use of health
services, institutional stay, use of medication and use of
services from general practice will be extracted from
longitudinal Danish registers [59-62]; The Danish
National Health Insurance Service Registry (NHSR) which
holds information on all contacts to general practice and
all services provided [63]; and The Danish Civil Registration
System (CRS), which has updated information on vital
status, e.g. day of death, on all Danish citizens. The register
is a key tool in Danish epidemiologic research [64].
Statistical analyses
Sample size
We expect the experimental interventions to reduce the
Copenhagen risk score during 12 months from baseline by
2.5% 10-year risk for coronary heart disease in patients
allocated to lifestyle coaching compared with the score in
patients allocated to care coordination alone, and a similar
reduction of 2.5% in care coordination compared to treat-
ment as usual as presented in Table 1. We plan to compare
all three groups and accordingly we reduced our alpha level
to 0.05/3 = 0.0166 [65]. Allowing a power of 90% we need
to recruit 150 patients to each intervention group for a total
of 450 patients. This calculation is based on an SD of 5.9%
of the Copenhagen risk score as found in the Inter99-
investigation [38].
Data analysis
Analysis of data will be based on the intention-to-treat
principle. I.e., all patients randomized will be included in
the analysis regardless of adherence to the allocated inter-
vention. The primary outcome and other continuous out-
comes will be analysed using a repeated measurement,
likelihood-based, mixed-effects model with an unstruc-
tured covariance matrix. This analysis will include meas-
urement at baseline and 12 months for the primary
outcome, and all measurements (baseline, 12 months, and
24 months post-intervention) for the follow-up results,
and is an appropriate approach to handling missing data.
Dichotomous outcomes will be analysed using logistic re-
gression. In case more than 5% of data is missing at follow
up we will use multiple imputation to handle missing data.
The imputations will be based on a linear regression
model with 100 imputations and 20 iterations. The pooled
analysis will subsequently be used for our analysis.
All statistical analysis will be conducted in SPSS. All
tests will be two-tailed and unless otherwise mentioned
the alpha level will be set at 0.01666.
Approval
Approval from the Danish Ethical Committee: H-4-
2012-051.
Approval from the Danish Data Protection Agency referral
number: 01689 RHP-2012-007.
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Discussion
Legitimacy of the study
Based on the growing mortality gap between schizo-
phrenic patients and people without schizophrenia, there
is an urgent need to improve the physical health in
patients with schizophrenia, allowing them to benefit from
the decline in cardiovascular disease that has been seen in
the general population in developed countries. A recent
Cochrane systematic review concluded that lifestyle
counselling is ineffective to prevent cardiovascular disease
in the general population, but recommends further
research in subgroups with high risk of cardiovascular dis-
ease, as they find a modest effect on patients with diabetes
or hypertension [66]. As the mortality from cardiovascular
disease is twice as high in patients with schizophrenia
compared to the general population, we find that the
former comprises such a subgroup. Furthermore, we
selected patients with increased waist circumference, due
to the correlations between central obesity and metabolic
disturbances [67]. Daumit et al. confirmed that weight loss
is possible in this subgroup, by offering group exercise on
a regular basis (three times a week) and free, healthy
meals. However, this is a costly intervention demanding a
reorganization of the outpatient care. With CHANGE we
have developed an alternative intervention, hoping that an
individualized approach integrated in the local area can be
effective and sustainable, as well as reaching out for those
with the most severe psychiatric and medical disabilities
that might not be ready to attain regular group exercise.
Statistical considerations
In line with current recommendations, our approach to
handling missing data has been described in the study
protocol [4]. Several methods have been used, including
complete analysis, which excludes participants with
missing outcomes or simple imputation where missing
values are substituted by ‘last observation carried forward’
or mean of the sample. These methods assume that
variables are missing completely at random, which is
usually not the case [68], and underestimate the precision
(standard error and confidence interval) [69]. Data are
missing at random, given all we have observed about a
person, the risk of missing a specific observation is inde-
pendent of the actual value of that observation. Following
this assumption, attempts can be made to substitute
missing values by using multiple imputation, where a
prediction model is used, and therefore accounts for the
uncertainty surrounding missing data values. As this as-
sumption of missing at are random is impossible to verify,
multiple imputation will be accompanied by a sensitivity
analysis, as recommended by the CONSORT guidelines
[70]. In our trial, this is especially crucial, as one might
speculate that participants lost to follow up had none or
even harmful effects of the lifestyle intervention, which
could be weight gain as a result of attempts to stop
smoking.
The problem of multiplicity arises in this trial due to
multiple interventions, multiple outcomes, and multiple
measurements (follow-up at both 12 and 24 months
after randomization), increasing the risk of type 1 error
(falsely rejecting the 0-hypothesis). To account for this,
analysis of primary and secondary outcomes will use a
Bonferroni-corrected alpha (0.05/3), hypothesising that
the lifestyle intervention will be superior to the care co-
ordination that will be superior to the treatment a usual.
This approach might be too conservative, due to a high
probability of correlation between the outcomes [65].
We therefore decided to calculate unadjusted p-values,
but interpret the results in accordance with values
described below:
Table 1 10 years risk of CVD calculated with Copenhagen risk score, WC =waist circumference, BP = blood pressure,
RHR = resting heart rate, HDL = high density lipoprotein, non-HDL = total cholesterol-HDL, HbA1c = glycosylated
haemoglobin, FEV1 = forced expiratory volume, VO2max =maximal oxygen uptake, sedentary = hours of physical
activity during leisure time spending ≤1.5 metabolic equivalents, MVPA = hours of moderate or vigorous activity
Variables Expected difference, mean Expected standard deviation α Power %
Primary outcome 10 years risk of CVD (%) 2.5 5.9 0.0166 0.90
Secondary outcomes WC (cm) 5 14 0.0166 0.75
BP (mm Hg) 5 12 0.0166 0.88
RHR (per minutes) 10 20 0.0166 0.97
HDL (mmol/l) 0.2 0.4 0.0166 0.97
Non-HDL (mmol/l) 0.45 1.1 0.0166 0.87
HbA1c (mmol/mol) 0.5 1.1 0.0166 0.94
FEV1 (L) -0.36 0.92 00166 0.84
VO2max 3.5 9 0.0166 0.73
Sedentary (minutes/day) 60 140 0.0166 0.90
MVPA (Minutes/day) 20 40 0.0166 0.97
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 P ≥0.05: The trial results could not demonstrate an
effect of the experimental intervention on the
secondary outcome.
 0.01 < P <0.05: The trial results indicate that there
may be a positive effect of the experimental
intervention on the secondary outcome. However,
the indication is not strong.
 0.001 < P <0.01: The trial results indicate that there
may be a positive effect of the experimental
intervention on the secondary outcome.
 P <0.001: The trial results strongly indicate that
there may be a positive effect of the experimental
intervention on the secondary outcome.
Outcomes
It is obvious that fatal and non-fatal cardiovascular out-
comes would be the optimal outcome for interventions
aiming to reduce mortality from cardiovascular disease.
Facing limited time and resources though, we chose to
focus on cardiovascular risk, and thus searched for the
most suitable risk score model, estimating 10-years risk.
The Copenhagen risk score is the best suitable in a Danish
population, and has incorporated data from randomized
clinical trials, thus making it the best model to estimate
changes in risk [71]. Furthermore, the Copenhagen risk
score can be used to estimate risk in patients with diabetes
and patients with a history of cardiovascular disease. As
was done in the population based study Inter99 [38], we
extrapolated the age at 60 years, to reach a substantial
level of risk, as no young persons have a high risk in spite
of unhealthy lifestyle habits and values highly above the
recommended. Additionally, by choosing a composite out-
come, we reduce the risk of multiplicity, without adjusting
the alpha-level.
A priori, we defined cardiorespiratory fitness as an
exploratory outcome, due to insecurity about the patients’
ability and acceptance of the ‘watt max test’. After com-
pleting data collection, it was redefined to key secondary
outcome. In a young high-risk population and in patients
with schizophrenia, traditional risk equations tend to
underestimate the risk, while cardiorespiratory fitness has
consistently been shown to correlate closely to cardiovas-
cular as well as all-cause mortality [72]. A major modifi-
able risk factor in the Copenhagen risk score is weight.
However, recent research has questioned relevance of
weight as outcome in lifestyle studies, as most patients
regain weight soon after a terminated intervention, and
solely focusing on weight reduction might have unhealthy
implications. Our sample has a low mean age and very
low cardiorespiratory fitness, and it might be just as clinic-
ally relevant for these patients to improve cardiorespira-
tory fitness than to lowering traditional risk factors for
cardiovascular disease.
Strengths and limitations
The CHANGE trial has several strengths. First, the de-
sign has central randomization, blinded outcome assess-
ments, data management, data analysis, and independent
funding [73-79]. Second, we planned our sample size to
avoid substantial type 2 errors. Third, we use a manual-
based, well described, and evidence-based theoretical
framework. Fourth, the approach has a high intensity
intervention, offering an assertive approach with at least
weekly personal contact. Fifth, we have a multifaceted
method, allowing the staff to work on all the known risk
factors. Sixth, our composite outcome integrates the re-
sults even though they might be heterogeneous. Seventh,
by comparing care-coordination with the lifestyle coach-
ing, we will be able to differentiate between the effect of
sufficient monitoring and treatment of somatic comor-
bidity and the effect of lifestyle changes, so a significant
difference between the two intervention groups will
point at an add-on effect of lifestyle coaching. Eighth, all
contacts, and the focus of the contact, with patients
are registered. Ninth, the intervention is developed to
be sustainable, using low-budget possibilities in the
neighbourhood to enable the patients to create long
lasting changes. Ninth, we will be able to follow pa-
tients through Danish publish register to assess any
long-term effects [80].
There are also limitations. Regarding some of the sec-
ondary outcomes, we will not have power to detect a
clinically relevant difference, for example smoking cessa-
tion, why this important outcome has been categorized
as an exploratory outcome. The thorough examination
at baseline might initialize some lifestyle changes in
patients randomized to the control group. The external
validity is directed by the selection of patients with
abdominal obesity; hence our results will only be valid
for this group of patients. Moreover, an unavoidably
limitation is also the selection bias created by a height-
ened motivation to change lifestyle habits, just by
accepting participation in the CHANGE trial. Choosing
a surrogate outcome like the Copenhagen risk score is a
limitation due to the risk scores possible inaccuracy in
predicting actual morbidity and mortality [81]. Further-
more, even though an individualized approach is neces-
sary in order to implement lifestyle changes in daily life,
it makes the trial vulnerable regarding its external valid-
ity, as not all patients will have the same interventions.
Conclusion
This paper describes the study protocol for a randomized
clinical trial to investigate the effectiveness of a tailored,
multifaceted health promotion intervention versus care
coordination versus treatment as usual in patients with
schizophrenia in outpatient care. The primary outcome is
the risk of cardiovascular disease assessed at 12 months.
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Secondary outcomes are physical health parameters,
health related behaviours, and psychometric measures.
The lifestyle coaching is developed to adapt to real life,
exploiting the possibilities of individual patients to create
long lasting lifestyle changes. There is limited evidence
to support the role of lifestyle interventions and care-
coordination in improving weight loss and reducing
metabolic risk in schizophrenia. Several smaller studies
have evaluated the effect of either physical activity or
diet or smoking cessation programs. However, larger
sample sizes and longer follow-up time are needed.
CHANGE will increase the evidence regarding physical
health in this vulnerable population, and enable clinicians
to provide treatment that will reduce the mortality gap.
Additional files
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